alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › immunogenicity

immunogenicity

3 studies tagged immunogenicity, dated 2023-06-29 to 2026-08-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study 2026-08-01
  2. Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial 2026-05-19
  3. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study 2023-06-29

Studies

3 studies carry this tag.

Date range

2023 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Alzheimer's research & therapy 1
  • EBioMedicine 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study

    ✓ Peer-reviewed alzhub usefulness score 87 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-08-01 Treatments

    ABvac40 showed favorable long-term safety and durable immunogenicity, supporting further clinical development.

  2. Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Alzheimer's research & therapy 2026-05-19 Treatments

    In this small Phase 1 study in early AD, ALZ‑101 was not associated with clear safety signals and elicited strong, durable Aβ‑specific antibody responses.

  3. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. EBioMedicine 2023-06-29 Treatments

    Between 7 December 2015 and 28 August 2018, 43 participants were randomised.

All topic tags with their study counts